Economic information and modeling report
Budget impact model
69 evidence topics · 58 sources
Lirafugratinib (Lyrfigtu)
Previously treated FGFR2 fusion or rearrangement-positive cholangiocarcinoma
- Manufacturer
- Elevar Therapeutics
- Regulatory submission
- NDA submitted January 2026
- Last updated